Healthcare -
Drug Manufacturers - General - NASDAQ - ES
$ 8.72
3.2 %
$ 7.27 B
Market Cap
33.54
P/E
1. INTRINSIC VALUE
Balance Sheet
Grifols, S.A.
| Current Assets | 5.73 B |
| Cash & Short-Term Investments | 1 B |
| Receivables | 1.08 B |
| Other Current Assets | 3.65 B |
| Non-Current Assets | 15.7 B |
| Long-Term Investments | 529 M |
| PP&E | 4.31 B |
| Other Non-Current Assets | 10.8 B |
| Current Liabilities | 2.16 B |
| Accounts Payable | 852 M |
| Short-Term Debt | 640 M |
| Other Current Liabilities | 664 M |
| Non-Current Liabilities | 10.6 B |
| Long-Term Debt | 9.45 B |
| Other Non-Current Liabilities | 1.2 B |
EFFICIENCY
Earnings Waterfall
Grifols, S.A.
| Revenue | 7.21 B |
| Cost Of Revenue | 4.42 B |
| Gross Profit | 2.79 B |
| Operating Expenses | 1.6 B |
| Operating Income | 1.19 B |
| Other Expenses | 748 M |
| Net Income | 444 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Grifols, S.A.
| Net Income | 444 M |
| Depreciation & Amortization | 438 M |
| Capital Expenditures | -371 M |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 22.4 M |
| Others | 36.3 M |
| Free Cash Flow | 531 M |
Wall Street Analysts Price Targets
Grifols, S.A.
GRFS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.456 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Grifols, S.A.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Grifols (GRFS) Is Up 2.47% in One Week: What You Should Know
Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
- 1 week ago
Is Grifols (GRFS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
- 2 weeks ago
GRFS vs. STVN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?
zacks.com
- 2 weeks ago
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the “Board”) expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. T.
businesswire.com
- 2 weeks ago
US court finds enough evidence to proceed with Grifols lawsuit against Gotham City
A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on Friday.
reuters.com
- 2 weeks ago
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
zacks.com
- 2 weeks ago
Grifols: If This Works Out, It Has Massive Upside
Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings. Recent Q1 2025 results confirm strong operational recovery: top-line growth, improved margins, and significant debt reduction, supporting my continued conviction. The primary risk is high leverage, but ongoing cash flow improvements and no dividend payout allow to focus on deleveraging, with dividend restoration likely by 2026.
seekingalpha.com
- 3 weeks ago
GRFS or NBIX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with the better value opportunity right now?
zacks.com
- 1 month ago
Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript
Grifols, S.A. (NASDAQ:GRFS ) Q1 2025 Earnings Conference Call May 12, 2025 12:30 PM ET Company Participants Danny Segarra - VP, IR and Sustainability Nacho Abia - CEO Rahul Srinivasan - CFO Roland Wandeler - President Biopharma Conference Call Participants Charles Pitman - Barclays Alvaro Lenze - Alantra Equities Jaime Escribano - Banco Santander Guilherme Sampaio - CaixaBank Danny Segarra Hello, everyone.
seekingalpha.com
- 1 month ago
Grifols says on course to meet 2025 outlook as net profit triples
Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.
reuters.com
- 1 month ago
IBL International collaborates with Grifols on advanced biomarker panels
MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a global healthcare company and leading producer of plasma-derived medicines and innovative diagnostic solutions, to transform the specialty diagnostics market. Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols' random access, single molecule coun.
businesswire.com
- 2 months ago
Brookfield resumes Grifols takeover talks, El Confidencial reports
Canadian investment fund Brookfield has resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols four months after a previous attempt fell through, news website El Confidencial reported on Wednesday, citing unidentified industry sources.
reuters.com
- 2 months ago
8. Profile
Summary
Grifols, S.A. GRFS
COUNTRY
ES
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 7.27 B
Dividend Yield
0.00%
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Contact
Avinguda de la Generalitat, 152, Barcelona, 08174
https://www.grifols.com
IPO
Date
June 2, 2011
Employees
23833
Officers
Mr. Jose Ignacio Abia Buenache
Chief Executive Officer & Director
Mr. Camille Alpi
Chief Human Resources & Talent Officer
Ms. Nuria Pascual Lapeña
Vice President of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer
Mr. David Ian Bell
Chief Corporate Affairs & Legal Officer
Mr. Enrique de la Torre
Chief Compliance Officer
Mr. Lluis Pons Gomez
Senior Vice President of Strategy & Chief Operating Officer Office
Mr. Vicente Blanquer Torre
Chief Quality Officer
Mr. Víctor Grifols Deu
Executive Director
Ms. Montse Ribas
Chief Communications and Reputation Officer
Mr. Rahul Srinivasan
Chief Financial Officer